Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
about
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentPharmacogenomics of breast cancer therapy: an updateGenome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levelsPharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationCYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with CyclophosphamideCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions.A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancerAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsHigher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descentGut microbiota-derived propionate reduces cancer cell proliferation in the liverPharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceCorrelation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.Lymphoma risk in systemic lupus: effects of disease activity versus treatmentEffect of an education program on knowledge, self-care behavior and handwashing competence on prevention of febrile neutropenia among breast cancer patients receiving Doxorubicin and Cyclophosphamide in Chemotherapy Day Centre.Pharmacogenetics of genes across the doxorubicin pathway.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Pharmacogenetics of chemotherapy efficacy in breast cancer.Drug-induced oxidative stress and toxicity.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia.Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.Drug transporters in breast cancer: response to anthracyclines and taxanes.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Pharmacogenomics and the treatment of acute myeloid leukemia.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting.Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Distinctiveness of the Roma population within CYP2B6 worldwide variation.Different transport activity of human triallelic MDR1 893Ala/Ser/Thr variant and its association with herb extracts.
P2860
Q26749954-88DC7736-6707-4F6E-A54A-2F7654B986C2Q27006783-33023D19-6850-4611-8667-F2EA3FD0C9DCQ27324181-4FC7A66D-E546-4062-A0E2-50552DA863BBQ28083875-6BDBB380-6D57-4A43-8D26-FB4E5963D716Q28552450-D3AAC469-3F4D-4F38-8D07-9EA130FED095Q30418239-494427CA-6E5A-4652-BAF7-195F26FEBEB1Q30584978-45E88827-3BAF-46D3-BC6A-9CCE534EE691Q33591401-7B341631-5858-4FAF-94A7-6557C1324A27Q34558816-434D1D0D-2569-4E96-8A83-7BC0B9F59EA0Q36100724-FC837033-0C52-4DB9-BDC0-A50E0B4F87A9Q36181844-F656E569-A639-4190-BED0-D1A9B59A06DDQ36236476-B7249F78-CC05-408F-9F25-9F3E6FF18353Q36384257-3C2BA8E4-D7BD-40A4-87DC-96685BB23216Q36387826-B02AFD93-CC1C-49F6-850F-9CEFD2FDFC07Q36489727-B1062F87-1767-4490-9E75-1BBC8531968EQ36550926-C3B3EC95-E97C-4B8A-B899-8AE8262B20FFQ36652629-63C97987-AF4B-4F5D-8DBE-27FEAD29D77AQ36657589-C5A59999-E5F5-43FA-9D98-D6D2EFA8AB65Q36948123-23917007-EA55-4EAD-8DD3-71DD43AE1AF3Q37374458-173708F9-2D2B-4F20-823F-B7463E285797Q37440949-A456FB7D-57BE-452C-8591-207F39E84657Q37932556-6792B6FB-E978-4822-AC99-DAF32540A18AQ37939200-61E8462C-2AB4-4707-9B38-441ADAF7DD2AQ38003703-4620686D-F593-4735-B3C8-7F88213C71C4Q38037517-97556096-156C-46BA-A8CD-BC96A7D1C3F7Q38047337-4CC74361-4ADA-4E65-8C2C-4FAE4FD3DEE9Q38063197-D35B275F-F8EB-49F2-8D7C-BD436D819577Q38092131-E643B0A2-94BF-4C68-9A0E-FA4D6A011BFFQ38271855-E669BDFD-E26E-4052-86AD-C76718870340Q38533459-25D68EF4-7B41-4F52-B891-19616C24B413Q38575008-9F389C97-5B85-40F7-81BF-85C8CB727D6FQ38704025-9FEBCDAC-8314-48CA-A82F-466F3314723CQ38887034-4A29249F-D145-4A15-B11D-FC2ABD6674B5Q38933314-5BF3BDE9-9BD6-40A8-A8F1-FFC002FA39BAQ39255407-869BAF10-CC4F-492E-B1C8-D90C1E76CEA7Q40040202-DE9D307D-5E2A-4A6F-9DB3-D2E00783FC96Q45924371-C3609CF8-B3E2-47CC-A840-5037D91F1ABBQ46250643-A225142D-7229-4D77-AF42-8204FFDA8B01Q47670434-EF494A14-738A-4756-AE89-D13699148ADDQ48682180-4E3D62A5-60A1-4DB4-B77F-BE088D0660B6
P2860
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@ast
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@en
type
label
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@ast
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@en
prefLabel
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@ast
Influence of pharmacogenetics ...... orubicin and cyclophosphamide.
@en
P2093
P2860
P356
P1476
Influence of pharmacogenetics ...... xorubicin and cyclophosphamide
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605587
P407
P577
2010-02-23T00:00:00Z
P5875
P6179
1033281818